Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Stockholm: Aph-1 and Pen-2: New Names in the Presenilin Debate Complete the Complex?
22 July 2002. Stockholm. One of the unresolved issues in the debate about γ-secretase revolves around the other members of the complex besides presenilin and nicastrin. If they were all isolated and better understood, it might be possible to reconstitute γ-secretase activity in vitro, a definitive experiment to prove the identity of γ-secretase.

A poster and a talk at the 8th International Conference on Alzheimer’s Disease and Related Disorders today presented new information on other protein members of the presenilin complex. The poster, by Jinhe Li at Pharmacia Corporation in Kalamzoo, Michigan, and colleagues there and at Exelixis Inc. in South San Francisco, described how C. elegans-based genetic screens for presenilin enhancers yielded three genes (aph-1, aph-2/nicastrin, and pen-2) that are required for presenilin function in Notch cleavage. The authors cloned the human homologs (aph-1a, aph-1b) and report that they are broadly expressed in different tissues. They also mapped aph-1a, pen-2 and nicastrin to chromosome regions reported to probably harbor AD risk genes. The work appeared in the July Developmental Cell.

The researchers used yeast two-hybrid assays and co-immunoprecipitation to detect interactions between aph-1b, pen-2, nicastrin , and presenilin 1. Aph-1, aph-1b and nicastrin appeared to reside in the ER in a pattern that resembles previous PS-1 localization studies. The poster proposes a complex consisting of presenilin, aph-1a, aph-1b, aph-2/nicastrin, and pen2. To test whether these new proteins can modulate Aβ generation, the scientists transfected HEK293 cells with aph-1a, aph-1b, and pen-2 versions bearing small deletions or substitutions and showed that these alterations affected Aβ levels.

Finally, the poster showed on nicastrin/pen-2 double knockout mice, showing they are embryonic lethal in much the same way as are presenilin1/2-double knockout mice, presumably due to impaired notch signaling.

As likely members of the γ-secretase complex, aph-1a, aph-1b, and pen-2 could be targets for drug development, the authors write, even as additional biological targets for γ-secretase keep emerging.

Working with Dennis Selkoe, Michael Wolfe, and others, Taylor Kimberly of Brigham and Women’s Hospital expanded these findings to his work with Chinese hamster ovary cells. Kimberly reported today that when overexpressing all three, aph-1, pen-2, and presenilin-1, γ-secretase activity shoots up in extracts of these cells when he added the substrate. In parallel, the authors saw increased generation of both Aβ and AICD, the intracellular cytoplasmic fragment of APP. (Nicastrin was already present in excess quantities in these cells.) “With these two additional components in hand, I now believe the γ-secretase complex is complete. We can now try to reconstitute activity in vitro,” said Selkoe.-Gabrielle Strobel.

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad